臨床検査62巻11号

2018年11月発行

今月の特集1 循環癌細胞（CTC）とリキッドバイオプシー

リキッドバイオプシーによる癌遺伝子変異検出

著者： 加藤菊也¹

所属機関： ¹奈良先端科学技術大学院大学先端科学技術研究科バイオサイエンス領域疾患ゲノム医学

ページ範囲：P.1434 - P.1441

Point

●リキッドバイオプシーは，血液中に滲出した腫瘍由来DNAの検出による新しい癌診断のアプローチである．

●次世代シークエンサーなどの新しい技術により，2010年代になってから急速に発展した．

●上皮成長因子受容体（EGFR）チロシンキナーゼ阻害剤（EGFR-TKI）のコンパニオン診断のように実用化された例もあるが，臨床有用性の検証例はあまりない．

●正常細胞の変異の混入など難しい問題を抱えており，さらなる研究開発が必要である．

参考文献

1）Leon SA, Shapiro B, Sklaroff DM, et al：Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res　37：646-650，1977

2）Stroun M, Anker P, Maurice P, et al：Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology　46：318-322，1989

3）Dressman D, Yan H, Traverso G, et al：Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A　100：8817-8822，2003

4）Lo YM, Zhang J, Leung TN, et al：Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet　64：218-224，1999

5）Diehl F， Li M， Dressman D, et al：Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A　102：16368-16373，2005

6）Diehl F, Schmidt K, Choti MA, et al：Circulating mutant DNA to assess tumor dynamics. Nat Med　14：985-990，2008

7）Abbosh C, Birkbak NJ, Wilson GA, et al：Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature　545：446-451，2017

8）Bettegowda C, Sausen M, Leary RJ, et al：Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med　6：224ra24，2014

9）Kato K, Uchida J, Kukita Y, et al：Transient appearance of circulating tumor DNA associated with de novo treatment. Sci Rep　6：38639，2016

10）Kinde I, Wu J, Papadopoulos N, et al：Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A　108：9530-9535，2011

11）Schmitt MW, Kennedy SR, Salk JJ, et al：Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A　109：14508-14513，2012

12）Kukita Y, Matoba R, Uchida J, et al：High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients. DNA Res　22：269-277，2015

13）Peng Q, Vijaya Satya R, Lewis M, et al：Reducing amplification artifacts in high multiplex amplicon sequencing by using molecular barcodes. BMC Genomics　16：589，2015

14）Lanman RB, Mortimer SA, Zill OA, et al：Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One　10：e0140712，2015

15）Newman AM, Lovejoy AF, Klass DM, et al：Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol　34：547-555，2016

16）Phallen J, Sausen M, Adleff V, et al：Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med　9，2017

17）Krimmel JD, Schmitt MW, Harrell MI, et al：Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci U S A　113：6005-6010，2016

18）Steensma DP, Bejar R, Jaiswal S, et al：Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood　126：9-16，2015

19）American Society of Clinical Oncology (ASCO)：Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. Presented Tuesday, June　5，2018（https://meetinglibrary.asco.org/record/161582/abstract）（最終アクセス：2018年8月31日）

20）Kukita Y, Ohkawa K, Takada R, et al：Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter. PLoS One　13：e0192611，2018

21）Mok TS, Wu Y-L, Ahn M-J, et al：Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med　376：629-640，2017

22）Soria JC, Ohe Y, Vansteenkiste J, et al：Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med　378：113-125，2018

23）Uchida J, Kato K, Kukita Y, et al：Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA. Clin Chem　61：1191-1196，2015

24）Kato K, Uchida J, Kukita Y, et al：Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients. Sci Rep　6：29093，2016

25）Taniguchi K, Uchida J, Nishino K, et al：Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res　17：7808-7815，2011

26）Diaz LA Jr, Williams RT, Wu J, et al：The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature　486：537-540，2012

27）Misale S, Yaeger R, Hobor S, et al：Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature　486：532-536，2012

28）Tie J, Wang Y, Tomasetti C, et al：Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med　8：346ra92，2016

29）Le Calvez-Kelm F, Foll M, Wozniak MB, et al：KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget　7：78827-78840，2016

30）Cohen JD, Javed AA, Thoburn C, et al：Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A　114：10202-10207，2017

31）Cohen JD, Li L, Wang Y, et al：Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science　359：926-930，2018

32）Merker JD, Oxnard GR, Compton C, et al：Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol　36：1631-1641，2018